The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2020

Filed:

Jan. 31, 2017
Applicant:

Intrexon Corporation, Blacksburg, VA (US);

Inventors:

Robert Eugene Hormann, Melrose Park, PA (US);

Bing Li, Shrewsbury, MA (US);

Assignee:

INTREXON CORPORATION, Blacksburg, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/63 (2006.01); C07D 333/38 (2006.01); C07C 243/38 (2006.01); C07C 281/02 (2006.01); C12N 15/82 (2006.01); A01N 37/18 (2006.01); A01N 43/08 (2006.01); A01N 43/10 (2006.01); A01N 43/30 (2006.01); A01N 43/32 (2006.01); A01N 43/40 (2006.01); C07C 241/04 (2006.01); C07C 269/06 (2006.01); C07C 271/08 (2006.01); C07D 213/82 (2006.01); C07D 307/68 (2006.01); C07D 317/68 (2006.01); C07D 319/18 (2006.01); C07D 217/24 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C07D 333/38 (2013.01); A01N 37/18 (2013.01); A01N 43/08 (2013.01); A01N 43/10 (2013.01); A01N 43/30 (2013.01); A01N 43/32 (2013.01); A01N 43/40 (2013.01); C07C 241/04 (2013.01); C07C 243/38 (2013.01); C07C 269/06 (2013.01); C07C 271/08 (2013.01); C07C 281/02 (2013.01); C07D 213/82 (2013.01); C07D 217/24 (2013.01); C07D 307/68 (2013.01); C07D 317/68 (2013.01); C07D 319/18 (2013.01); C12N 15/8217 (2013.01); C12N 15/8238 (2013.01); A61K 48/00 (2013.01); C07B 2200/07 (2013.01); C07C 2601/14 (2017.05);
Abstract

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.


Find Patent Forward Citations

Loading…